Email this article The condition of mammary glands in women with diabetes mellitus type 1
- Authors: Musina E.V.1, Kogan I.Y.1, Borovik N.V.1
-
Affiliations:
- Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
- Issue: Vol 67, No 3 (2018)
- Pages: 38-43
- Section: Articles
- URL: https://journals.rcsi.science/jowd/article/view/9083
- DOI: https://doi.org/10.17816/JOWD67338-43
- ID: 9083
Cite item
Full Text
Abstract
Background. The pathogenesis of diabetic mastopathy is unknown. It is assumed that one of the important factors in the development of this disease may be hyperglycemia.
The aim of this study was to evaluate the clinical manifestations and echographic features of the mammary gland structure in women with diabetes mellitus type 1.
Materials and methods. The three groups of women were examined: group 1: women with type 1 diabetes, with the onset of the disease before menarche (n = 58); group 2: women with type 1 diabetes, with the onset of the disease after menarche (n = 56); group 3: women with fibrocystic mastopathy, without diabetes mellitus type 1 (n = 79). Mastalgia was evaluated using the visual analogue scale. The ultrasound examination of mammary glands was performed on day 5 to 7 of the menstrual cycle.
Results. The patients of all groups complained of mastalgia. Mammary gland ultrasound revealed that the thickness of the glandular tissue in patients of the first group was significantly less than in the second and third group. The diameter of the milk ducts was also significantly different in patients in each study group. In the group of patients with fibrocystic mastopathy without diabetes mellitus type 1, the tissue echogenicity is average in 41.8% of subjects, with it elevated in 58.2% of individuals. Moreover, in groups of patients with diabetes, 90% of subjects have increased echogenicity of breast tissue.
Conclusion. Diabetic mastopathy is characterized by a fibrotic echo version of the organ parenchyma, which can be caused by a violation of the mammary gland formation and function in patients with diabetes mellitus type 1.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina V. Musina
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Author for correspondence.
Email: umo_otta@mail.ru
MD, PhD, Director of the Curriculum and Instruction Department
Russian Federation, Saint PetersburgIgor Yu. Kogan
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: ncotta@mail.ru
MD, PhD, DSci (Medicine), Professor, Corresponding Member of RAS, Interim Director
Russian Federation, Saint PetersburgNatalia V. Borovik
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: borovik1970@yandex.ru
MD, PhD
Russian Federation, Saint PetersburgReferences
- Soler NG, Khardori R. Fibrous disease of the breast, thyroiditis, and cheiroarthropathy in type I diabetes mellitus. Lancet. 1984 Jan 28;1(8370):193-5.
- Khan F, Naab T, Cooke-Sampson E. Diabetic Mastopathy, a Rare Fibroinflammatory Breast Disease. Am J Clin Pathol. 2016;146(suppl. 1):264. doi: 10.1093/ajcp/aqw159.035.
- Розен В.Б. Основы эндокринологии. - М.: Изд-во МГУ, 1994. - 384 с. [Rozen VB. Osnovy jendokrinologii. Moscow: Izd-vo MGU, 1994. P. 384. (In Russ.)]
- Moschetta M, Telegrafo M, Triggiani V, et al. Diabetic mastopathy: a diagnostic challenge in breast sonography. J Clin Ultrasound. 2015;43(2):113-7. doi: 10.1002/jcu.22246.
- Tomaszewski JE, Brooks JS, Hicks D, Livolsi VA. Diabetic mastopathy: a distinctive clinicopathologic entity. Hum Pathol. 1992;23(7):780-6.
- Копнин Б.П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза // Биохимия. - 2000. - Т. 65. - № 1. - С. 5-33. [Kopnin BP. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry (Moscow). 2000;65(1):2-27. (In Russ.)]
- Bayer U, Horn LC, Schulz HG. Bilateral, tumorlike diabetic mastopathy-progression and regression of the disease during 5-year follow up. Eur J Radiol. 1998;26(3):248-53.
- Johansen D, Stocks T, Jonsson H, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2307-17. doi: 10.1158/1055-9965.EPI-10-0234.
- Jiralerspong S, Gonzalez-Angulo AM, Hung MC. Expanding the arsenal: metformin for the treatment of triple-negative breast cancer? Cell Cycle. 2009;8(17):2681. doi: 10.4161/cc.8.17.9647.
- Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42-51. doi: 10.1200/JCO.2002.20.1.42
- Schwartz IS, Strauchen JA. Lymphocytic mastopathy. An autoimmune disease of the breast? Am J Clin Pathol. 1990;93(6):725-30.
- Chan CL, Ho RS, Shek TW, Kwong A. Diabetic mastopathy. Breast J. 2013;19(5):533-8. doi: 10.1111/tbj.12158.
- Seidman JD, Schnaper LA, Phillips LE. Mastopathy in insulin-requiring diabetes mellitus. Hum Pathol. 1994;25(8):819-24.
- Dorokhova O, Fineberg S, Koenigsberg T, Wang Y. Diabetic mastopathy, a clinicopathological correlation of 34 cases. Pathol Int. 2012;62(10):660-664. doi: 10.1111/j.1440-1827.2012.02853.
- Pereira MA, de Magalhães AV, da Motta LD, et al. Fibrous mastopathy: clinical, imaging, and histopathologic findings of 31 cases. J Obstet Gynaecol Res. 2010;36(2):326-35. doi: 10.1111/j.1447-0756.2009.01146.x.
- Берштейн Л.М., Ковалевский А.Ю., Порошина Т.Е., и др. Прогенотоксический сдвиг в маммарном жире (адипогенотоксикоз): связь с клиническими и биологическими особенностями рака молочной железы // Вопросы онкологии. - 2008. - Т. 54. - № 3. - С. 294-302. [Berstein LM, Kovalevskij AYu, Poroshina TE, et al. Progenotoxic shift in mammary adipose tissue (adipogenotoxicosis): association with clinical and biological characteristics of breast cancer. Problems in Oncology. 2008;54(3):294-302. (In Russ.)]
- Bjørge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1737-45. doi: 10.1158/1055-9965.EPI-10-0230.
- Коваленко И.Г., Берштейн Л.М., Семиглазов В.Ф., и др. Рецепторный статус опухолей у курящих и страдающих сахарным диабетом больных раком молочной железы //Вопросы онкологии. - 2005. - № 2. - С. 187-191. [Kovalenko IG, Bershtejn LM, Semiglazov VF, et al. Receptornyj status opuholej u kurjashhih i stradajushhih saharnym diabetom bol’nyh rakom molochnoj zhelezy. Problems in Oncology. 2005;(2):187-191. (In Russ.)]
- Чумаченко П.А., Хмельницкий О.К., Шлыков И.П. Молочная железа и эндокринный гомеостаз. - Воронеж, 1987. - 128 с. [Chumachenko PA, Hmel’nickij OK, Shlykov IP. Molochnaja zheleza i jendokrinnyj gomeostaz. Voronezh; 1987. (In Russ.)]
- Гуркин Ю.А. Современный взгляд на лечение девочек и девушек, страдающих патологией молочных желез // Журнал акушерства и женских болезней. - 2000. - № 3. - С. 55-58. [Gurkin JuA. Sovremennyj vzgljad na lechenie devochek i devushek, stradajushhih patologiej molochnyh zhelez. Journal of Obstetrics and Women’s Diseases. 2000;(3):55-8. (In Russ.)]
